Latest National Institute of Allergy and Infectious Diseases Stories

NIH researchers show parasites create feeding ion channels in blood cellsSnug inside a human red blood cell, the malaria parasite hides from the immune system and fuels its growth by digesting hemoglobin, the cell's main protein. The parasite, however, must obtain additional nutrients from the bloodstream via tiny pores in the cell membrane. Now, investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have found the...

Two Institutions, along with the NIH National Institute of Allergy and Infectious Diseases, will Convene Conference on May 30-June 1, 2011, to Discuss Infectious Disease in South Africa SAN DIEGO, May 25, 2011 /PRNewswire-USNewswire/ -- The J. Craig Venter Institute (JCVI) today announced the signing of a memorandum of understanding with the University of Limpopo (UL) in South Africa to expand ongoing research collaborations on a variety of levels including in human genomics and prostate...

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), report that they have developed a method"”10,000 times more sensitive than other methods"”to detect variant Creutzfeldt-Jacob disease (vCJD) in blood plasma. vCJD is a type of prion disease in humans that leads to brain damage and death. The NIAID researchers also used the test to rapidly detect scrapie, a prion disease of sheep, in infected hamsters, some...

Finding Could Aid Development of HIV Vaccine for HumansWHAT: Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). The researchers found that neutralizing antibodies generated by immunization were associated with protection against SIV infection. This finding marks an important step toward understanding how an effective HIV...

MILFORD, Mass., May 5, 2011 /PRNewswire/ -- Spring Bank Pharmaceuticals today announced it has been awarded an RO1 grant from the National Institute of Health, National Institute of Allergy and Infectious Diseases for the development of SB 9200, a novel, orally bioavailable agent for the treatment of Hepatitis B virus infection. Under the terms of this award, Spring Bank Pharmaceuticals will receive $3.9 million over five years in support of its development efforts. This is the fourth...

ROCKVILLE, Md., April 28, 2011 /PRNewswire-USNewswire/ -- A new genetic study on leprosy bacteria reports that armadillos may be a source of infection in the Southern United States. The collaboration between scientists at the Health Resources and Services Administration's (HRSA) National Hansen's Disease Program (NHDP) in Baton Rouge, La., the Ecole Polytechnique Federale de Lausanne and Institute Pasteur in Europe, and the Instituto de Biomedicina in Venezuela sheds light on the potential...

NIH scientists review lessons learned from more than a decade of trialsIn the past 12 years, four large-scale efficacy trials of HIV vaccines have been conducted in various populations. Results from the most recent trial"”the RV144 trial in Thailand, which found a 31 percent reduction in the rate of HIV acquisition among vaccinated heterosexual men and women"”have given scientists reason for cautious optimism. Yet building on these findings could take years, given that traditional HIV...

The Company's adjuvant gives 70% prevention of infection in primates Atlanta, GA (Vocus/PRWEB) April 12, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN). Specifically, the HVTN plans to clinically test a novel vaccine...

ATLANTA, April 11, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN). Specifically, the HVTN plans to clinically test a novel vaccine product developed by GeoVax scientists that expresses human...

MENLO PARK, Calif., March 28, 2011 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, and Collaborative Drug Discovery (CDD), provider of a web-based drug discovery software platform, announced that they have been awarded a grant to support the first year of a software development project focused on tuberculosis drug discovery efforts. The Phase I Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy...